Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB10.NEO and Bempegaldesleukin in Advanced Solid Tumors
NCT03548467Phase 2Completed
- Sponsor
- Nykode Therapeutics
- Start
- Apr 2018
- Primary completion
- Jan 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of VB10.NEO in melanoma, non-small cell lung cancer (NSCLC), clear cell renal cell carcinoma (ccRCC), urothelial carcinoma (UC), squamous cell carcinoma of the head and neck (HNSCC), sponsored by Nykode Therapeutics. Started Apr 2018; status: completed.
02
Drugs
VB10.NEO
03
Conditions
melanomanon-small cell lung cancer (NSCLC)clear cell renal cell carcinoma (ccRCC)urothelial carcinoma (UC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03548467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03548467.